Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma

Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myelomaLenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma, Published online: 27 April 2018; doi:10.1038/s41409-018-0177-6Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma

https://www.nature.com/articles/s41409-018-0177-6

Source: Bone Marrow Transplantation - April 27, 2018 Category: Hematology Authors: Jennifer Huang Sharon Phillips Michael Byrne Wichai Chinratanalab Brian G. Engelhardt Stacey A. Goodman Shelton L. Harrell Madan Jagasia Adetola Kassim Kyle T. Rawling Bipin N. Savani Salyka Sengsayadeth R. Frank Cornell Source Type: research